HIV pre-exposure prophylaxis (PrEP) is a prevention strategy which includes the regular or event-driven use of antiretroviral medication to prevent HIV infection in adults. Several clinical trials ...

Multiple pre-exposure (PrEP) and postexposure (PEP) treatments are now available to prevent HIV infection. An updated Canadian guideline published in CMAJ (Canadian Medical Association Journal) ...

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

Kenya will this year begin rolling out a new long-acting injectable HIV prevention drug, Lenacapavir, positioning the country ...

Real-world data show DoxyPEP implementation among PrEP users significantly reduces the incidence of chlamydia and syphilis.

HIV pre-exposure prophylaxis (PrEP) is an effective and safe intervention for individuals with behaviors that are considered high risk for acquiring HIV infection. Despite the success of this ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

Among individuals using HIV pre-exposure prophylaxis (HIV PrEP), doxycycline post-exposure prophylaxis (doxyPEP) was associated with a substantial decline in chlamydia and syphilis incidence.

MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that ...

Kenya has taken a major step towards expanding HIV prevention options after the Ministry of Health formally recommended the ...